Genomic analyses have revealed that a prominent feature in patients with abdominal aortic aneurysm (AAA) as well as in the angiotensin II (Ang II) experimental model is metabolic reprogramming, characterized by enhanced glycolysis and suppressed glucose oxidative phosphorylation. The gene discussed is AGT; the disease is triple-A syndrome.